Sector
PharmaceuticalsOpen
₹9.05Prev. Close
₹9.5Turnover(Lac.)
₹0.01Day's High
₹9.05Day's Low
₹9.0552 Week's High
₹052 Week's Low
₹0Book Value
₹77.79Face Value
₹10Mkt Cap (₹ Cr.)
30.83P/E
0.59EPS
13.49Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2014 | Dec-2012 | Dec-2011 | Dec-2010 |
---|---|---|---|---|
Equity Capital | 34.07 | 34.07 | 54.07 | 34.07 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 504.56 | 513.29 | 611.03 | 665.17 |
Net Worth | 538.63 | 547.36 | 665.1 | 699.24 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Dec-2012 | Dec-2011 |
---|---|---|
Revenue | 475.06 | 412 |
yoy growth (%) | 15.3 | |
Raw materials | -403.73 | -258.43 |
As % of sales | 84.98 | 62.72 |
Employee costs | -28.91 | -35.39 |
Y/e 31 Mar( In .Cr) | Dec-2012 | Dec-2011 |
---|---|---|
Profit before tax | -30.37 | 35.55 |
Depreciation | -8.3 | -8.23 |
Tax paid | -0.84 | -10.19 |
Working capital | 30.92 | |
Other operating items |
Y/e 31 Mar | Dec-2012 | Dec-2011 |
---|---|---|
Growth matrix (%) | ||
Revenue growth | 15.3 | |
Op profit growth | -119.9 | |
EBIT growth | -80.76 | |
Net profit growth | -79.03 |
Particulars (Rupees in Crores.) | Mar-2015 | Mar-2014 | Dec-2013 | Dec-2012 | Dec-2011 |
---|---|---|---|---|---|
Gross Sales | 757.93 | 2,059.8 | 1,746.78 | 1,631.54 | 1,557.04 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 757.93 | 2,059.8 | 1,746.78 | 1,631.54 | 1,557.04 |
Other Operating Income | 7.2 | 38.63 | 39.93 | 22.14 | 84.3 |
Other Income | 0 | 0 | 1.5 | 8.31 | 0.03 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,614 | 122.93 | 3,87,276.66 | 1,181.05 | 0.84 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,568.7 | 71.3 | 1,47,802.29 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,461.75 | 25.37 | 1,18,061.19 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,059 | 56.75 | 1,03,513.97 | 485 | 0.92 | 2,330 | 222.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,140.1 | 18.33 | 95,026.5 | 849.4 | 0.7 | 4,997.8 | 322.46 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Shashikant Patel
Additional Director
Pranav Koshal
Additional Director
Jignesh Jitendra Panchal
Additional Director
Milindkumar Laxmishankar Dixit
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Plethico Pharmaceuticals Ltd
Summary
Plethico Pharmaceuticals Limited (PPL), an emerging global healthcare company was incorporated on 4th December 1991 as a private limited. PPL is engaged in the business of manufacturing, marketing and distribution of a broad range of pharmaceutical and allied healthcare products, with operations in several key markets in India and internationally. Domestically, Plethico operates in the segments of Sports Nutrition, Confectionary and OTC, in India. The companys robust product portfolio includes renowned, international brands such as Herbal healthcare products, Food Supplements and Pharma OTC. PPL having its presence in more than 60 countries including India, adding US, UK, Australia, Korea & HK recently after acquiring Natrol and the distribution focus in US, UK, CIS and deepening reach in SEA in Cambodia, Vietnam & Philippines. The Companys status and name was changed in the year 1992, converted from private limited to public limited company, consequent to change, the word private was deleted in the name and was rebuild to the present name Plethico Pharmaceuticals Limited from Plethico Pharmaceuticals Private Limited. Subsequently, the company had received the fresh incorporation certificate on 27th August 1992. During the period from inception to the year 2000, PPL had introduced the novel herbal products for Hepatocare, Diabetes and Syndrome X developed with in-house research and clinical evidence and also committed with major thrust into International Marketing. Travisil,
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.